Mevisiran - EnhancedBio
Alternative Names: ENB-201; ENB-401Latest Information Update: 28 Apr 2025
At a glance
- Originator EnhancedBio
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Phosphomevalonate kinase inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in South Korea (Parenteral)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer in South Korea (Parenteral)
- 08 Apr 2021 EnhancedBio has patent protection for mevisiran (EnhancedBio pipeline, March 2021)